eflornithine
eflornithine: developed by 1 company · 5 clinical trials tracked.
eflornithine evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
How could eflornithine → SNBP affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| PANBELA THERAPEUTICS, INC. (SNBP) Gastric cancer, Type 1 diabetes, metastatic castration-resis… | Phase 2 |
Clinical Trials (5)
An Intermediate Expanded Use Trial of DFMO
A Phase II Open Label Basket Trial Study Using Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Primary endpoint: Number of Cohort 1 participants with relapse free survival (RFS) during study
A Phase I/II Study Using Eflornithine (DFMO) and AMXT 1501 for Relapsed and Refractory Neuroblastoma, CNS Tumors, and Sarcomas
Primary endpoint: Phase I- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Repeat Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer: The APEX (Androgen and Polyamine Elimination Alternating With Xtandi) Trial
Primary endpoint: PSA response rate at Cycle 1 Day 64
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma
Primary endpoint: Number of days from start of therapy to date of first relapse
Frequently asked questions
Who is developing eflornithine?
eflornithine is being developed by PANBELA THERAPEUTICS, INC..
How many clinical trials involve eflornithine?
BioSniper tracks 5 clinical trials involving eflornithine.